BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27913493)

  • 1. Novel agents in follicular lymphoma: choosing the best target.
    Sehn LH
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):284-292. PubMed ID: 27913493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.
    Boughan KM; Caimi PF
    Curr Oncol Rep; 2019 May; 21(7):63. PubMed ID: 31119485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of follicular lymphoma - Why does it happen and can it be prevented?
    Link BK
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):49-56. PubMed ID: 29452666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
    Fowler N
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of microenvironment in follicular lymphoma.
    Nowakowski GS; Ansell SM
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):169-73. PubMed ID: 25696851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma.
    Pon JR; Marra MA
    Blood; 2016 Jan; 127(2):181-6. PubMed ID: 26447189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
    Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
    Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Agents in Follicular Lymphoma.
    Ysebaert L; Morschhauser F
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: evolving therapeutic strategies.
    Kahl BS; Yang DT
    Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
    Cánovas A; Alonso JJ; Barreiro G; Aguirre C
    Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Follicular Lymphoma.
    Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
    Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for relapsed and refractory follicular lymphoma.
    Cheah CY; Fowler NH
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):41-48. PubMed ID: 29452665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of genetic targets for guiding clinical management of follicular lymphoma.
    Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA
    Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of follicular lymphoma: current status.
    Tilly H; Zelenetz A
    Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model.
    Andjelić B; Todorović-Balint M; Antić D; Bila J; Djurašinović V; Mihaljević B
    Vojnosanit Pregl; 2015 Jan; 72(1):26-32. PubMed ID: 26043587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.